Kentucky Retirement Systems Insurance Trust Fund Decreases Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Kentucky Retirement Systems Insurance Trust Fund decreased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 7.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,693 shares of the medical research company’s stock after selling 134 shares during the quarter. Kentucky Retirement Systems Insurance Trust Fund’s holdings in Charles River Laboratories International were worth $459,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the business. Blue Trust Inc. increased its position in Charles River Laboratories International by 21.9% during the fourth quarter. Blue Trust Inc. now owns 985 shares of the medical research company’s stock valued at $233,000 after acquiring an additional 177 shares during the last quarter. Patriot Financial Group Insurance Agency LLC increased its position in Charles River Laboratories International by 5.7% during the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 1,126 shares of the medical research company’s stock valued at $266,000 after acquiring an additional 61 shares during the last quarter. Fifth Third Bancorp increased its position in Charles River Laboratories International by 5.1% during the fourth quarter. Fifth Third Bancorp now owns 12,062 shares of the medical research company’s stock valued at $2,851,000 after acquiring an additional 580 shares during the last quarter. Norris Perne & French LLP MI increased its position in Charles River Laboratories International by 27.1% during the fourth quarter. Norris Perne & French LLP MI now owns 131,993 shares of the medical research company’s stock valued at $31,203,000 after acquiring an additional 28,103 shares during the last quarter. Finally, DAVENPORT & Co LLC bought a new position in shares of Charles River Laboratories International in the fourth quarter worth about $1,904,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Insider Transactions at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 1,304 shares of the company’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $226.97, for a total transaction of $295,968.88. Following the sale, the executive vice president now directly owns 23,276 shares of the company’s stock, valued at approximately $5,282,953.72. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 1.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on CRL. TD Cowen lowered their price objective on shares of Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating for the company in a research note on Monday, May 13th. The Goldman Sachs Group began coverage on shares of Charles River Laboratories International in a report on Thursday, June 6th. They issued a “buy” rating and a $290.00 price target on the stock. Argus reaffirmed a “hold” rating on shares of Charles River Laboratories International in a report on Friday, June 28th. Mizuho began coverage on shares of Charles River Laboratories International in a report on Friday, June 7th. They issued a “neutral” rating and a $235.00 price objective for the company. Finally, Barclays began coverage on shares of Charles River Laboratories International in a research note on Friday, June 28th. They set an “equal weight” rating and a $230.00 target price for the company. Eight investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Charles River Laboratories International has an average rating of “Hold” and a consensus target price of $252.29.

Charles River Laboratories International Trading Up 1.3 %

NYSE:CRL traded up $3.13 on Monday, hitting $236.60. The stock had a trading volume of 292,405 shares, compared to its average volume of 532,912. The company has a quick ratio of 1.37, a current ratio of 1.75 and a debt-to-equity ratio of 0.73. The stock has a market cap of $12.19 billion, a price-to-earnings ratio of 27.47, a PEG ratio of 2.23 and a beta of 1.38. The company has a fifty day moving average price of $212.96 and a two-hundred day moving average price of $230.32. Charles River Laboratories International, Inc. has a 1-year low of $161.65 and a 1-year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Thursday, May 9th. The medical research company reported $2.27 EPS for the quarter, topping the consensus estimate of $2.05 by $0.22. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $997.24 million. Equities research analysts expect that Charles River Laboratories International, Inc. will post 10.99 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).